Rhesus D Prophylaxis in the Emergency Department: Essential FRCEM SBA Practice Questions Explained

Rhesus D (RhD) prophylaxis sits at the intersection of obstetric medicine and emergency care, and it is precisely the kind of topic that appears deceptively straightforward in practice yet catches candidates out in the FRCEM SBA exam. The clinical stakes are high: failure to administer anti-D immunoglobulin (anti-D Ig) at the correct dose and within the correct time window after a sensitising event is a preventable cause of haemolytic disease of the fetus and newborn (HDFN) in future pregnancies. Emergency physicians must therefore have a confident, guideline-grounded command of the indications, contraindications, dosing thresholds, and escalation criteria that govern this intervention. These are exactly the competencies that well-constructed FRCEM SBA practice questions are designed to probe.

Clinical Context: Why This Matters in the Emergency Department

The ED is frequently the first point of contact for RhD-negative pregnant women presenting with sensitising events outside the scheduled antenatal pathway. These include threatened, incomplete, and complete miscarriage; ectopic pregnancy and its management; antepartum haemorrhage; and abdominal trauma in pregnancy, including seemingly minor blunt injury to the gravid abdomen. The volume of feto-maternal haemorrhage (FMH) required to cause sensitisation is as little as 0.1 mL of RhD-positive red cells, which means even a low-velocity road traffic collision or a fall onto the abdomen may be clinically significant.

Without prophylaxis, RhD sensitisation occurs in approximately 16% of RhD-negative women who carry an RhD-positive fetus to term following delivery. First-trimester sensitising events carry a lower, but not negligible, risk. The widespread adoption of routine antenatal anti-D prophylaxis (RAADP) under NICE guidance has substantially reduced HDFN incidence in the UK; however, the ED remains a gap in this safety net, particularly in women who present before booking or who experience trauma at any gestation.

The RCOG and NICE guidelines on the use of anti-D Ig for RhD prophylaxis provide the authoritative framework for UK practice, and the Royal College of Emergency Medicine expects emergency physicians at registrar level and above to apply these confidently. This is reflected in the RCEM curriculum mapping for obstetric emergencies and underpins the clinical scenarios you will encounter in FRCEM SBA exam questions on this topic.

Pathophysiology: The Immunological Basis of RhD Sensitisation

The RhD antigen is encoded by the RHD gene on chromosome 1 and is expressed as a transmembrane protein on the surface of red blood cells. It is among the most immunogenic blood group antigens known. RhD-negative individuals lack this antigen entirely and do not produce anti-D antibodies under normal circumstances. However, when RhD-negative red cells are exposed to RhD-positive cells through FMH, a primary immune response is mounted. This generates IgM anti-D antibodies initially, followed by class switching to IgG.

It is the IgG anti-D fraction that is clinically dangerous in subsequent pregnancies. IgG crosses the placenta via neonatal Fc receptors (FcRn-mediated transport) and can bind to RhD-positive fetal red cells, causing haemolysis. The resulting HDFN ranges in severity from mild neonatal jaundice to profound fetal anaemia, hydrops fetalis, and intrauterine death. The primary immune response following the initial sensitising event is often clinically silent; it is the amplified secondary response in a subsequent pregnancy that causes harm.

Anti-D Ig works by passive immunisation. Exogenous anti-D antibodies bind to and facilitate clearance of any RhD-positive fetal cells in the maternal circulation before they can trigger a primary immune response. This mechanism requires that anti-D Ig be administered before the immune response becomes established, which defines the critical 72-hour window.

ED Assessment and Management

Establishing the Clinical Picture

The essential initial steps are to confirm the woman’s RhD status (from her handheld maternity notes or from direct laboratory testing), establish gestation as accurately as possible (last menstrual period, ultrasound dates), characterise the nature of the sensitising event, and determine whether she has pre-existing anti-D antibodies. Group and screen should be sent from the ED. The hospital transfusion laboratory must be notified promptly so that anti-D Ig can be prepared without delay.

Dosing Framework

Current NICE and RCOG guidance, as summarised in the NICE Clinical Knowledge Summaries on Rhesus D prophylaxis, recommends the following framework for non-sensitised RhD-negative women:

• Before 12 weeks gestation: Anti-D Ig is indicated only for ectopic pregnancy, molar pregnancy, therapeutic termination of pregnancy, or uterine instrumentation. Threatened miscarriage and spontaneous complete miscarriage below 12 weeks do not routinely require anti-D Ig if conservative management is adopted and there is no heavy or prolonged bleeding. If there is clinical uncertainty, escalate to obstetrics.
• 12 to less than 20 weeks gestation: Anti-D Ig 250 IU intramuscularly is indicated for all sensitising events, including surgical or medical management of miscarriage, ectopic pregnancy, antepartum haemorrhage, and abdominal trauma.
• At or after 20 weeks gestation: Anti-D Ig 500 IU intramuscularly is the minimum dose. A Kleihauer-Betke test (acid elution test) must be performed to quantify FMH and determine whether additional doses are required. One standard 500 IU vial covers a FMH of approximately 4 mL of fetal red cells; larger haemorrhages require additional dosing calculated from the laboratory result in conjunction with the transfusion team.

The Kleihauer-Betke Test

The Kleihauer-Betke (acid elution) test exploits the resistance of fetal haemoglobin (HbF) to acid elution. When a maternal blood film is treated with acid, adult haemoglobin is eluted from maternal red cells, leaving them as ghost cells, while fetal red cells containing HbF remain intact and stain darkly. The proportion of stained fetal cells in the maternal sample allows quantification of the FMH volume, enabling calculation of the total anti-D Ig dose required. This test is mandatory for all sensitising events at or after 20 weeks gestation and should be arranged via the transfusion laboratory. Results must be interpreted in the clinical context, as conditions that elevate maternal HbF (such as sickle cell disease or certain haemoglobinopathies) can introduce artefact.

Timing and Escalation

Anti-D Ig must be administered within 72 hours of the sensitising event for maximum efficacy. Where there is genuine uncertainty about the timing of an event, or where clinical circumstances mean the 72-hour window may be missed, the BMJ and specialist guidance acknowledge that administration up to 10 days may still confer partial protection and should not be withheld on grounds of delay alone. Escalation to obstetrics is required for any sensitising event at or after 20 weeks gestation, for complex trauma, for cases where the FMH calculation suggests a large haemorrhage, and wherever there is diagnostic uncertainty about gestational age or the nature of the event.

How the FRCEM SBA Exam Tests This Topic

The FRCEM SBA exam is structured around single-best-answer clinical scenarios drawn directly from the RCEM curriculum. RhD prophylaxis appears within the obstetric and gynaecological emergencies domain, and questions are typically scenario-based rather than purely factual recall. The examiners construct stems that require candidates to integrate gestational age, the nature of the sensitising event, the timing of presentation, and the woman’s known immunological status to arrive at the single best management decision.

Common question formats include: a woman at 10 weeks presenting with vaginal bleeding following blunt abdominal trauma, asking whether anti-D Ig is indicated and at what dose; a woman at 22 weeks who has had a minor road traffic collision with no apparent injury, asking what investigation is required in addition to anti-D Ig; and a woman with known anti-D antibodies from a previous sensitisation presenting with antepartum haemorrhage, where the correct answer is that anti-D Ig is not indicated because she is already sensitised.

The FRCEM SBA clinical scenarios in this area frequently exploit the distinction between the under-12-weeks threshold (where indications are narrow) and the 12-to-20-week and post-20-week thresholds (where indications broaden and the required dose changes). Candidates who memorise the dose without understanding the gestational boundary are consistently disadvantaged. Linking this material to structured FRCEM SBA revision through our MRCEM Single Best Answer revision course at EM Learning Centre will sharpen your ability to parse these stems efficiently.

Revision Pearls: High-Yield Facts for the Exam

1. The sensitising FMH volume is as little as 0.1 mL of RhD-positive red cells. Even minor abdominal trauma in pregnancy must be taken seriously in an RhD-negative woman.
2. Anti-D Ig 250 IU covers events before 20 weeks; 500 IU is the minimum for events at or after 20 weeks.
3. The 72-hour window is the target for maximum efficacy, but up to 10 days post-event may still provide some protection and administration should not be withheld solely because of elapsed time within this window.
4. Threatened miscarriage below 12 weeks without heavy bleeding does not routinely require anti-D Ig. Ectopic pregnancy and uterine instrumentation at any gestation do require it.
5. A Kleihauer-Betke test is mandatory after sensitising events at or after 20 weeks to guide total dosing; do not omit this investigation in your answer.
6. Anti-D Ig is not indicated if the woman is already RhD-sensitised (pre-existing anti-D antibodies detected on group and antibody screen).
7. If a woman’s RhD status is unknown in the ED and a sensitising event has occurred, do not delay: send blood urgently, contact the transfusion laboratory, and discuss with obstetrics while awaiting results.
8. Anti-D Ig is a blood-derived product. Consent must be obtained and documented, and the product administered as per local transfusion policy, with appropriate traceability documentation.

Common Pitfalls: Where Candidates Lose Marks

• Applying the 500 IU dose to an event occurring at 18 weeks, where 250 IU is correct (the 20-week threshold is the discriminator).
• Administering anti-D Ig to a woman already known to have anti-D antibodies on her booking screen, where prophylaxis is futile and not indicated.
• Failing to request a Kleihauer-Betke test for a post-20-week sensitising event, or selecting a management option that omits this investigation.
• Assuming that a threatened miscarriage at 8 weeks with light spotting requires anti-D Ig. Under current NICE guidance, it does not, provided there is no instrumentation and the pregnancy is continuing conservatively.
• Confusing the timing rule: 72 hours is the optimal window, but candidates who select an option that permanently withholds anti-D Ig because the 72-hour mark has been passed are incorrect.
• Neglecting to escalate to obstetrics and the transfusion laboratory for events at or after 20 weeks. The ED’s role is to initiate, not to manage this in isolation.

How EM Learning Centre Supports Your MRCEM Single Best Answer Revision

Mastering topics like RhD prophylaxis requires more than reading guidelines in isolation. You need to practise applying them under exam conditions, with well-constructed clinical scenarios that mirror the format and difficulty of the actual FRCEM SBA practice questions you will encounter. The EM Learning Centre is built specifically for this purpose, offering a structured curriculum aligned to the RCEM syllabus, high-quality SBA question banks with detailed explanations, and focused revision modules across the full breadth of emergency medicine.

Obstetric and gynaecological emergencies, including RhD prophylaxis, are covered in depth within our MRCEM Single Best Answer revision course at EM Learning Centre, alongside related lessons covering acute allergy, anaphylaxis, and angioedema presentations that frequently appear alongside obstetric scenarios in the exam. If you are working through your FRCEM SBA exam preparation and want a reliable, evidence-based question bank with academic-level explanations, EM Learning Centre provides the structured environment to make that revision count.

References

1. National Institute for Health and Care Excellence. Rhesus negative women: routine antenatal anti-D prophylaxis. NICE Clinical Knowledge Summaries. NICE (nice.org.uk)
2. Royal College of Emergency Medicine. RCEM Curriculum and Obstetric Emergencies. RCEM (rcem.ac.uk)
3. BMJ Best Practice. Haemolytic disease of the fetus and newborn. The BMJ (bmj.com)
4. NHS. Rhesus disease. NHS (nhs.uk)